Trevena Inc (TRVN) - Total Liabilities
Based on the latest financial reports, Trevena Inc (TRVN) has total liabilities worth $42.50 Million USD as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Trevena Inc's assets to evaluate the company's liquid asset resilience ratio.
Trevena Inc - Total Liabilities Trend (2011–2023)
This chart illustrates how Trevena Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Trevena Inc asset portfolio.
Trevena Inc Competitors by Total Liabilities
The table below lists competitors of Trevena Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CareMax Inc
NASDAQ:CMAX
|
USA | $601.80 Million |
|
Auddia Inc
NASDAQ:AUUDW
|
USA | $669.25K |
|
Pure One Corporation Limited
AU:P1E
|
Australia | AU$11.54 Million |
|
Keras Resources PLC
LSE:KRS
|
UK | GBX2.67 Million |
|
Biocept Inc.
NASDAQ:BIOCQ
|
USA | $21.81 Million |
Liability Composition Analysis (2011–2023)
This chart breaks down Trevena Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Trevena Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Trevena Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Trevena Inc (2011–2023)
The table below shows the annual total liabilities of Trevena Inc from 2011 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $48.26 Million | +45.89% |
| 2022-12-31 | $33.08 Million | +113.49% |
| 2021-12-31 | $15.49 Million | -34.54% |
| 2020-12-31 | $23.67 Million | +39.93% |
| 2019-12-31 | $16.92 Million | -33.01% |
| 2018-12-31 | $25.25 Million | -33.70% |
| 2017-12-31 | $38.09 Million | +5.59% |
| 2016-12-31 | $36.07 Million | +11.95% |
| 2015-12-31 | $32.22 Million | +252.78% |
| 2014-12-31 | $9.13 Million | +168.53% |
| 2013-12-31 | $3.40 Million | -58.15% |
| 2012-12-31 | $8.13 Million | +103.67% |
| 2011-12-31 | $3.99 Million | -- |
About Trevena Inc
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the… Read more